Decoy Therapeutics
DCOY
6 hedge funds and large institutions have $532K invested in Decoy Therapeutics in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 4 → 6 (+2)
0% less ownership
Funds ownership: 0% → 0% (-0%)
37% less capital invested
Capital invested by funds: $840K → $532K (-$308K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$487K |
| 2 |
Renaissance Technologies
New York
|
+$243K |
| 3 |
Bank of New York Mellon
New York
|
+$60.9K |
Top Sellers
DCOY Hedge Fund Activity: Q1 2020 in Review
6 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q1 2020, worth a combined $532K — down 37% from $840K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new DCOY positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Worth Venture Partners, opening a new position worth an estimated $487K.
- 6 institutional investors held Decoy Therapeutics (DCOY) as of Q1 2020, up from 4 in Q4 2019.
- Funds reported $532K of Decoy Therapeutics stock for Q1 2020, down 37% quarter-over-quarter.
- 2 funds opened new Decoy Therapeutics positions in Q1 2020 and 0 closed out, a net change of +2 holders.
- The largest Decoy Therapeutics buyer in Q1 2020 was Worth Venture Partners, an estimated $487K added.
Based on aggregated 13F filings for Q1 2020.